ABSTRACT
Introduction
Endometrial hyperplasia represents a nonphysiological, noninvasive proliferation of the endometrium that results in a morphologic pattern of glands with irregular shapes and varying size¹. There are two forms of hyperplasia, one (atypical) that is closely related to adenocarcinoma, being an apparent precursor lesion, and another (nonatypical) that is largely self-limited with little apparent relationship to carcinoma².
Acording to World Health Organization (WHO), the endometrial hyperplasia is classified in nonatypical hyperplasias (typical) -simple hyperplasia without atypia, complex hyperplasia without atypia -and atypical hyperplasias -simple atypical hyperplasia and complex atypical hyperplasia. Correct identification and classification of hyperplasia are especially important in endometrial biopsy and curettage specimens because proper diagnosis guides clinical therapy³, which can be very different depending on the type of hyperplasia found. This pathologic entity is detected in up to 25% of women with abnormal bleeding that were submitted to diagnostic hysteroscopy [4] [5] [6] . The atypical hyperplasias presents a higher risk for adenocarcinoma progression and, in 40% of cases, it can occur with concomitant invasive neoplasia 7 . The endometrium is a hormone-dependent tissue and a high percentage of endometrial tumors express estrogenic and/ or progestagenic receptors. Estrogen promotes endometrial proliferation, whereas progesterone inhibits this proliferation 8 .
The progesterone-induced estrogen-opposed effect is obtained through the reduction of cellular receptors to estrogen and through the induction of target-cell enzymes that convert estradiol into estrone sulfate, an excreted metabolite. Consequently, the number of estrogenic receptor complexes that are retained in the cell nuclei is decreased, such as estradiol intracellular viability. In addition, progestagenic agents suppress estrogenic-induced oncogenetic transcription 8 .
Progestins, which are synthetic derivatives of progesterone that have antiestrogenic activity after binding to partial response, have been used for patients with endometrial tumors. The efficacy of megesterol acetate and medroxyprogesterone acetate for patients with advanced endometrial tumors has been reported for relatively short periods 9, 10 . In previous studies including 30 patients treated with hormonal therapy in which 28 patients were treated with medroxyprogesterone acetate, 24 patients (80%) were classified as complete response, partial response, or stable disease 11 . It should be noted that long-term use of high-dose progestin therapy is associated with adverse effects such as weight gain, severe depression, and thromboembolic complications 12 .
Aromatase inhibitors were developed as therapeutic effectors for estrogen-dependent cancers and are being used in malignant breast tumors in post-menopausal patients 13 .
Aromatase inhibitors can reduce the levels of estrogen by inhibiting estrogen synthesis in peripheral sites, which leads to a reduction in the receptor-mediated growth stimulated in estrogen We used 48 BALB/c female mice, 11 weeks old, from CEBIO (Animal Care Center of UFMG, Belo Horizonte, MG, Brazil). The animals were kept in aseptic and ventilated cages at an average temperature of 22ºC with a 12-h light/dark cycle.
Filtered water and rodent chow (Labina ® , Purina) were given ad libitum. The average water ingestion was 5 mL/animal/ day at the beginning of the experiment. Before drug administration, mice were kept for seven days in these conditions for ambient adaptation. 
Drugs and vehicles

Experimental model inducing endometrial hyperplasia
Drugs were administered via different routes. According to Takahashi et al. 19 , bilateral intrauterine injections of ENU were made using Gelco/Angiocath 45 mm/23 G, through the mouse cervix. We used subcutaneous injections for estrogen 19, 20 , intramuscular injections for progestagen 21 and oral administration of letrozole. Female BALB/c mice were treated daily letrozole (10 microg/day) every four weeks 22, 23 . Eleven week-old females were weighed and divided into four groups -I, II, III and IV.
The experimental design is illustrated in Table 1 . All the animals received an intrauterine injection of ENU (12.5 mg/kg) diluted in PEG, under anesthesia (xylazine 0.02 mL + ketamine 0.04 mL), except for group I (control), which received vehicle. Groups II (ENU + EHB), III (ENU + EHB + MPA) and IV (ENU + EHB + Ltz) received EHB injections weekly (100 μg/kg), group III received MPA injections every 4 weeks (weeks 1, 4, 8, 12 and 16) at 2 mg/kg 23 , while group IV received Ltz diluted in drinking water at 3 μg/mL, according to the recommended dose for humans (0.6 mg/kg/day) 22, 23 . 
Obtaining blood and tissue samples
Sixteen weeks after ENU administration, the animals were anesthetized again; blood samples were obtained by medial orbital sinus puncture and then sacrificed by cervical dislocation and necropsied. Blood samples were immediately centrifuged and serum was kept at -20ºC until processing. Uteri were resected and fixed in a 10% buffered formalin solution for posterior histological analysis.
Hormone quantification
Serum samples were analyzed for estradiol (E2) levels, by electrochemiluminescence and chemiluminescence, respectively. Hormone levels were expressed by pg/mL (E2).
Histological studies
After formalin fixation, uterus samples were embedded in paraffin; the slices were stained in hematoxilin and eosin (H&E).
For each whole uterus (including cervix), we obtained transverse slices; histological analysis was performed by a pathologist physician who did not know the animal group identification (a blind study).
Endometrial proliferative lesions were classified into four categories of hyperplasia -low, moderate, severe, and adenocarcinoma³. Low and moderate hyperplasias were characterized by discrete architectural alterations in glands, presenting variable volume, irregular shapes and frequent cystic transformations (Figure 1 Classification criteria for severe hyperplasia included high epithelial proliferation in the glands with stratification and cellular atypias, besides the irregular shape of the glands.
Adenocarcinoma was classified based on intense and irregular gland proliferation and its juxtaposition (without circumjacent stroma), atypical covering and muscular layer invasion.
Statistic analysis
Data were collected, digitalized in SPSS for Windows 16.0 software (SPSS Inc., Chicago, IL, USA). Differences between groups were evaluated with student's t test and ANOVA (hormone levels) and chi-square test (histological analysis). Statistical significance was considered for p<0.05. The sample group of 12 mice per group was enough to evaluate differences superior to 55% for endometrial proliferative lesion proportions (confidence interval = 95% and statistical power 80%).
Results
During the experiment, three deaths were recorded: two animals from Group II (ENU + EHB) and one animal from Group IV (ENU + EHB + Ltz).
Hormone quantification
As illustrated in Figure 2 , group II (ENU + EHB) showed higher serum levels of E2 compared to the group I (control) 
Histological evaluation
No endometrial hyperplasia was evident in 27 animals, however low hyperplasia was detected in 5 animals, and moderate hyperplasia was detected in 13 animals. We did not register animals with severe hyperplasia or endometrial adenocarcinoma (Table 2) . Endometrial hyperplasia, or any sign of endometrial proliferative lesion, was not detected in group I (control). A higher incidence of hyperplasic lesions was observed in group II (ENU + EHB) compared to group I. When compared to group III (ENU + EHB + MPA), group II (ENU + EHB) showed a higher incidence and degree of this kind of lesion (70% of moderate hyperplasia and 30% of the cases with uterine cavity edema and endometrial atrophy, without hyperplasia) ( Table 3 ). The incidence of low proliferative lesions was significantly higher too, compared to group I (control) (p<0.05). There was no statistical difference for the occurrence of endometrial hyperplasia between groups II (ENU + EHB) and IV (ENU + EBH + Ltz). In group III (ENU + EHB + MPA), we observed the highest rate of hyperplasia, compared to group I (control) (p<0.05). For group IV (ENU + EHB + Ltz), we observed a higher rate of endometrial hyperplasia when compared to groups I (control) and III (ENU + EHB + MPA) (p<0.05), but it was statistically similar to group II (ENU + EHB), (p>0.05).
Discussion
The present study showed that 70% of mice developed moderate hyperplasia after 16 weeks of ENU + EHB exposure.
Similarly to the previously cited study, we obtained cases of estrogen-stimulated and carcinogen-initiated hyperplasia. We did not observe cases of endometrial adenocarcinoma, which could be justified by the short period of drug exposition or to the lower dose of carcinogen used, as discussed previously.
Effect of letrozole in carcinogen-plus-estrogen-induced endometrial hyperplasia in mice
Acta Cirúrgica Brasileira -Vol. 31 (4) In the Tulay Kilic-Okman et al. 13 investigation, the effects of letrozole were compared to that caused by clomiphene citrate in rat ovarian follicles, endometrium and hormonal levels.
Oral letrozole suppressed blood and urinary estrogenic levels and caused similar effects to clomiphene citrate in the follicular growth stimulation. Endometrial thickness was similar between the groups; supporting the idea that letrozole could have direct antiestrogenic effects in the endometrium. In cited studies, aromatase inhibitor drugs were used in the experimental treatment of tumors, in vivo or in vitro, but there was no approach for their action in carcinogenic process of endometrium. We expected that the dose of letrozole we used could act as a protective antiestrogenic agent in the process of inducing endometrial proliferative lesions, but this action was not observed in our study. We could suppose that letrozole does not act as an inhibitor of exogenous endometrial estrogenic function. The estradiol dose was identical for all the experimental groups, which confirms that letrozole was not able to diminish serum estradiol levels in group IV (ENU + EHB + Ltz).
Data for the group that received a progestagenic compound -MPA -showed a protective role for this drug for endometrial proliferation. Curiously, this action was not observed in the letrozole-treated group, where no evidence of endometrial proliferative protection was detected. Letrozole has been used in breast and endometrium malignant tumors already installed, with evidences that could exist estrogenic depletion in tumoral site by aromatase inhibition 28 . This action was not supported by the present study. We evaluated the effect of this drug in the process of endometrial proliferative induction utilizing exogenous estrogen.
This could justify the lack of inhibition of this kind of lesion by letrozole.
Experimental evaluations of the endometrial carcinogenesis process are limited for many clinical, technical and ethical reasons. One of the strengths of this study is the novelty of evaluating the endometrial effects of Ltz in a carcinogen+estrogen-induced endometrial hyperplasia experimental model. The problem studied here is very complex and this study also has limitations as the definition of the experimental model regarding the dose of the drugs used, the time of stimulation and the classification of the endometrial lesions originally described in women. Another limitation of the present study is how to extrapolate animal data to human. However, a better understanding of the intratumoral action of aromatase in estrogenic-dependent malignant tumors, such as endometrioid endometrial carcinoma, could contribute to the potential development of endocrine therapy with aromatase inhibitors.
Conclusions
Medroxy progesterone acetate partially inhibited the development of endometrial proliferative lesions in mice with ENU+HBE-induced endometrial hyperplasia. There was no evidence that letrozole could act as an antiestrogenic drug in the development of these endometrial proliferative lesions.
